Furthermore, the proportion of high‐risk or ETP‐ALL patients in the TNFAIP3 mutation subgroup was higher than that in the TNFAIP3 wild‐type subgroup (high risk: 100% vs. 62%; ETP‐ALL: 100% vs. 25%) (Figure 4A,B, middle panels). This evidence concerns the gene TNFAIP3 and acute lymphoblastic leukemia.